The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS

Completed · Not applicable

Conditions studied: HIV Infections

In brief

To determine safety and tolerance of administering aerosolized recombinant interferon gamma (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of IFN-gamma can activate alveolar macrophages in AIDS patients.

Key facts

Study ID

NCT00002433

Run by

Amgen

People needed

12

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• Diagnosis of AIDS with one or more opportunistic infections.
• Kaposi's sarcoma with prior history of opportunistic infection.
• Stable dose of zidovudine (AZT) therapy.
• Preserved pulmonary, renal and hepatic function.

You may not qualify if…

• Co-existing Condition:
• Patients with the following conditions or symptoms are excluded:
• Presence of active infection.
• Active opportunistic infections.
• Cardiac disease.
• Central nervous system disorders.
• History of seizures.
• Irreversible airway disease.
• Patients with the following are excluded:
• Co-existing conditions and symptoms listed in Patient Exclusion Co-existing Conditions.
• Prior Medication:
• Excluded within 4 weeks of study entry:
• Immunosuppressive therapy.
• Cytotoxic therapy.
• Excluded:
• Interferon gamma therapy.

Where it is running

• New York Hosp - Cornell Med Ctr — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.